‘Unbelievably important moment’: Sarepta clears the air on manufacturing, payers ahead of gene therapy adcomm

Amber Tong

The topic that dominated Sarepta’s first quarter earnings call was one execs couldn’t talk much about: the upcoming advisory committee meeting for its gene therapy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Unbelievably important moment’: Sarepta clears the air on manufacturing, payers ahead of gene therapy adcomm

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Major FDA staff cuts would slow drug reviews, experts say

Updated: Bay Area biotech VC to shut down 15 months after launch, sources say, after key investor pulls out

Senators ask FDA to dig into 'misleading' Super Bowl ad from Hims

Bain buys Mitsubishi Tanabe Pharma in $3.3B bet on Japan

Roche heads to FDA with Gazyva results in a form of lupus

A fourth person receives gene-edited pig kidney, first in three-person study

‘Un­be­liev­ably im­por­tant mo­ment’: Sarep­ta clears the air on man­u­fac­tur­ing, pay­ers ahead of gene ther­a­py ad­comm

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

‘Unbelievably important moment’: Sarepta clears the air on manufacturing, payers ahead of gene therapy adcomm